Guest guest Posted October 7, 2011 Report Share Posted October 7, 2011 I have found this event - intended for oncologists - to be the best venue for keeping up with clinical practice, controversies, and research in lymphoma. The CLL Session is on Friday (below) registration: http://www.lymphomaandmyeloma.com/2011/registration.html ===== Saturday, October 22, 2011 Welcome and audience survey Morton , MD LYMPHOMA SESSION 8:05 am: Introduction to Lymphoma Session P. Leonard, MD Session X: Lymphoma biology Moderator: Rita Shaknovich, MD 8:10 am: New molecular targets in large cell lymphoma M. Rimsza, MD 8:25 am: BCL-6: a regulator of lymphomagenesis Ari Melnick, MD 8:40 am: Panel discussion and questions == Session XI: Hodgkin’s disease Moderator: Elstrom, MD 8:50 am: Limited treatment for limited disease? Volker Diehl, MD 9:10 am: Emerging new agents in Hodgkin’s and lymphoma Friedberg, MD 9:30 am: Is there a role for consolidation radiation in limited and advanced Hodgkin’s disease in the era of PET scan? , MD 9:50 am: Panel discussion and questions === Session XII: Special lectures in Lymphoma Moderator: Morton , MD 10:25 am: Presentation of best lymphoma abstract 10:35 am: The SASS Foundation for Medical Research Award Ceremony Francis P. Arena, MD - President & Director of Research for the SASS Foundation Presentation: Ultmann Award for Contributions to Lymphoma Research Presenters: Morton , MD and P. Leonard, MD Recipient: Bertrand Coiffier, MD 10:40 am: Is R-CHOP-21 still the standard for all patients or is there a role for CHOP-14, ABVCP, EPOCH, etc? Bertrand Coiffier, MD 11:00 am: The Bruce Waterfall Memorial Lecture in Waldenstrom’s Macroglobulinemia Presenter: Morton , Md Moderator: , MD Treatment approaches for untreated and relapsed disease M. Ansell, MD, PhD 11:25 am: Panel discussion and questions === Session XIII: Follicular lymphoma Moderator: Leonard, MD 1:40 pm: Pre-debate audience survey Debate: Should everyone receive maintenance rituximab? Yes: Maloney, MD, PhD No: Bruce E. Cheson, MD Post-debate audience survey 2:20 pm: Pre-debate audience survey Debate: Is “watch and wait” passé in asymptomatic follicular lymphoma? Yes: P. Leonard, MD No: Myron Czuczman, MD Post-debate audience survey 3:00 pm: Panel discussion and questions === Session XIV: Aggressive lymphoma Moderator: , MD 3:15 pm: Pre-session audience survey 3:25 pm: Relapsed aggressive lymphoma: what approaches are applicable for transplant eligible and ineligible patients? What has the CORAL study taught us? Craig Moskowitz, MD 3:45 pm: Mantle cell lymphoma: How best to approach and treatment: Is there a role for maintenance? Brad Kahl, MD 4:05 pm: Double hit aggressive lymphoma Kieron Dunleavy, MD 4:25 pm: Pre-session audience survey 4:35 pm: Panel discussion and questions ==== CLL SESSION - Friday 1:10 pm: Introduction to CLL Session Furman, MD Session VIII: Treatment approaches I Moderator: Furman, MD 1:15 pm: Pre-session audience survey 1:25 pm: Introduction to The Prince Family Lecture 1:30 pm: The Prince Family lecture: Is a cure on the horizon? J. Keating, MD 1:55 pm: Molecular pathogenesis and therapy of CLL J. Kipps, MD, PhD 2:15 pm: Transplantation in CLL: How major a role? Edwin Alyea, MD 2:35 pm: Post-session audience survey 2:45 pm: Panel discussion and questions ==Session IX: Treatment approaches II Moderator: Kanti Rai, MD 3:20 pm: Pre-session audience survey 3:30 pm: Treatment of the elderly: How gentle should it be? Neil E. Kay, MD 3:50 pm: Non-chemotherapeutic approaches: Can we avoid alkylators and purine analogues? O’Brien, MD 4:10 pm: Novel approaches to CLL: Exciting new agents Furman, MD 4:30 pm: Post-session audience survey 4:40 pm: Panel discussion and questions Patients Against Lymphoma www.Lymphomation.org Evidence-based information on lymphoma, independent of health industry funding Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.